This trial is conducted in Japan. The aim of this trial is to investigate the pharmacokinetics of biphasic insulin aspart 50 (NN-X14Mix50) and biphasic insulin aspart 70 (NN-X14Mix70) in Japanese healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
Novo Nordisk Investigational Site
Tokyo, Japan
Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 70)
Cmax, maximum insulin aspart concentration
tmax, time to maximum insulin aspart concentration
t½, terminal elimination half life
Mean residence time (MRT)
Area under the curve from time 0 to infinity (0-∞)
Area under the insulin aspart curve in the interval from 0 to 24 hours (BIAsp 50)
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.